A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

AIDS

Volumn 12, Issue 16, 1998, Pages

  Staszewski, Schlomo ^a   Katlama, Christine ^b   Harrer, Thomas ^c   Massip, Patrice ^d   Yeni, Patrick ^e   Cutrell, Amy ^f   Tortell, Stephanie M ^f   Harrigan, Richard P ^f   Steel, Helen ^g   Lanier, Randall E ^f   Pearce, Gillian ^g  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Hôpital Pupan   (France)

^e BICHAT HOSPITAL   (France)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

1592U89; Abacavir; Antiretroviral therapy; Combination therapy; Lamivudine; Viral load; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; EAR INFECTION; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; NOSE INFECTION; PAIN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SLEEP DISORDER; VERTIGO; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; LAMIVUDINE; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 7844224756     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00001     Document Type: Article

References (8)

1. Daluge SM, Good SS, Faletto MB, et al.: Abacavir, a novel carbocyclic nucleoside analog with potent selective anti-human mmunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41:1082-1093.
2. Tisdale M, Alnadaf T, Cousens D: Combination of mutations in human immunodeficiency virus type 1 reverse transcriplase required for resistance to the carbocyclic nucleoside analogue abacavir. Antimicrob Agents Chemother 1997, 41: 1093-1098.
3. Saag M. Sonnerborg A, Torres RG, et al.: Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-1-infected adults. AIDS 1998, 12:F 203-F209.
4. Farder BA, Kohli A, Kellam P, et al.: Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993, 365:671-673.
5. Boucher CA, Keulen W, van Bommel I, et al.: Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from subject sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996, 40:2404-2409.
6. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. Massari F, Conant M, Mellors J, et al.: A phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine didanosine in antiretroviral naive subjects. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 200].
8. Mathez D, De Truchis P, Gorin I, et al.: Ritonavir, AZT, DDC, as a triple combination in AIDS subjects. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstarct 285].